Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $6.56 Million Registered Direct Offering

Press Release – New York, NY – January 25, 2021 – Sichenzia Ross Ference LLP today announced that it represented Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, in a registered direct offering of 1,250,000 American Depositary Shares (ADSs), each representing 600 of the Company’s ordinary shares, at a purchase price of $5.25 per ADS.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The ADSs had been registered on a registration statement on Form F-3 (File No. 333-237152) declared effective by the Securities and Exchange Commission on March 23, 2020.

The Sichenzia Ross Ference LLP team was led by partners Darrin M. Ocasio, Avital Perlman and Jeffrey Cahlon and associate Yian Pan.

• Author
• Recent Posts

Sichenzia Ross Ference Carmel LLP

SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

• Sichenzia Ross Ference Carmel LLP Represents Sharps Technology in $400 Million Private Placement - August 28, 2025
• 美国思成律师事务所代表Dominari Securities、Pacific Century Securities和Revere Securities完成Curanex Pharmaceuticals纳斯达克上市 - August 27, 2025
• Sichenzia Ross Ference Carmel LLP Represents Dominari Securities in $15 Million Initial Public Offering of Curanex Pharmaceuticals - August 27, 2025